S
46.78
-0.75 (-1.58%)
| Previous Close | 47.53 |
| Open | 47.37 |
| Volume | 2,906,309 |
| Avg. Volume (3M) | 4,004,600 |
| Market Cap | 112,077,873,152 |
| Price / Earnings (TTM) | 20.16 |
| Price / Earnings (Forward) | 9.29 |
| Price / Sales | 2.09 |
| Price / Book | 1.34 |
| 52 Weeks Range | |
| Earnings Date | 23 Apr 2026 |
| TTM Dividend Yield | 4.73% |
| Profit Margin | 13.95% |
| Operating Margin (TTM) | 20.78% |
| Diluted EPS (TTM) | 2.94 |
| Quarterly Revenue Growth (YOY) | -4.60% |
| Quarterly Earnings Growth (YOY) | 65.20% |
| Total Debt/Equity (MRQ) | 23.01% |
| Current Ratio (MRQ) | 1.46 |
| Operating Cash Flow (TTM) | 9.08 B |
| Levered Free Cash Flow (TTM) | -4.94 B |
| Return on Assets (TTM) | 4.28% |
| Return on Equity (TTM) | 7.30% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - General (US) | Bullish | Mixed |
| Drug Manufacturers - General (Global) | Bullish | Mixed | |
| Stock | Sanofi | Mixed | Bearish |
AIStockmoo Score
-0.3
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.25 |
|
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Investment Style | Large Core |
| % Held by Institutions | 10.49% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Mondrian Investment Partners Ltd | 31 Dec 2025 | 4,495,348 |
| Natixis Advisors, Llc | 31 Dec 2025 | 3,234,911 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Feb 2026 | Announcement | Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion |
| 03 Feb 2026 | Announcement | Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion |
| 02 Feb 2026 | Announcement | Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease |
| 30 Jan 2026 | Announcement | Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease |
| 30 Jan 2026 | Announcement | Press Release: Sanofi’s Rezurock recommended for EU approval by the CHMP to treat chronic graft-vs-host disease |
| 29 Jan 2026 | Announcement | Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026 |
| 29 Jan 2026 | Announcement | Press release: 2025: strong sales and EPS growth. Continued profitable growth expected in 2026 |
| TTM Dividend Yield | 4.73% |
| 5Y Average Dividend Yield | 4.99% |
| Payout Ratio | 75.37% |
| Ex Date | Announcement Date | Payment Date | Details |
|---|---|---|---|
| 04 May 2026 | 14 Apr 2026 | 03 Jun 2026 | 2.422477 Cash |
| 09 May 2025 | 15 Apr 2025 | 12 Jun 2025 | 2.212154 Cash |
| 09 May 2024 | 26 Mar 2024 | 06 Jun 2024 | 2.037356 Cash |
| 09 May 2024 | 26 Mar 2024 | 06 Jun 2024 | 2.0369079 Cash |
| 30 May 2023 | - | 23 Jun 2023 | 1.9000852 Cash |
| 26 May 2022 | - | 27 Jun 2022 | 0.2971788 Cash |
| 04 May 2022 | 20 Apr 2022 | 31 May 2022 | 1.7967514 Cash |
| 03 May 2021 | 23 Mar 2021 | 26 May 2021 | 1.906064 Cash |
| 30 Apr 2020 | 05 Mar 2020 | 26 May 2020 | 1.6993994 Cash |
| 07 May 2019 | - | 31 May 2019 | 1.722322 Cash |
| 09 May 2018 | 07 Feb 2018 | 04 Jun 2018 | 1.860874 Cash |
| 11 May 2017 | 16 Feb 2017 | 07 Jun 2017 | 1.577088 Cash |
| 05 May 2016 | 19 Feb 2016 | 01 Jun 2016 | 1.630252 Cash |
| 06 May 2015 | 25 Feb 2015 | 02 Jun 2015 | 1.618087 Cash |
| 17 May 2010 | 12 Feb 2010 | 14 Jun 2010 | 1.62732 Cash |
| 04 Jun 2007 | 05 Mar 2007 | 03 Jul 2007 | 1.14537 Cash |
| 02 Jun 2006 | 06 Mar 2006 | 03 Jul 2006 | 0.912 Cash |
| 02 Jun 2005 | 01 Mar 2005 | 01 Jul 2005 | 0.7993 Cash |
| Show more | |||
Annual Dividend Yield
| Year | Annual Dividend ($) | Frequency/Year | Yield % |
|---|---|---|---|
| 2026 | 2.42 | 1 | 5.18 |
| 2025 | 2.21 | 1 | 4.57 |
| 2024 | 4.07 | 2 | 8.45 |
| 2023 | 1.90 | 1 | 3.82 |
| 2022 | 2.09 | 2 | 4.32 |
| 2021 | 1.91 | 1 | 3.81 |
| 2020 | 1.70 | 1 | 3.50 |
| 2019 | 1.72 | 1 | 3.43 |
| 2018 | 1.86 | 1 | 4.29 |
| 2017 | 1.58 | 1 | 3.67 |
| 2016 | 1.63 | 1 | 4.03 |
| 2015 | 1.62 | 1 | 3.79 |
| 2010 | 1.63 | 1 | 5.05 |
| 2007 | 1.15 | 1 | 2.52 |
| 2006 | 0.912 | 1 | 1.98 |
| 2005 | 0.799 | 1 | 1.82 |
| Show more | |||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |